Sabin Vaccine Institute [to 18 July 2015]
:: Sabin PDP Advances World’s First Human Hookworm Vaccine
WASHINGTON, D.C. — July 13, 2015 — The Sabin Vaccine Institute (Sabin) today released updates on its product development partnership (Sabin PDP) and five Phase 1 clinical trials for two vaccine candidates for human hookworm, one of the most common neglected tropical diseases (NTDs).
These studies would not have been possible without broad collaboration across organizations and disciplines. Funding was provided by the Bill & Melinda Gates Foundation, the Dutch Ministry of Foreign Affairs and the European Commission FP7 Programme. The Infectious Disease Research Institute (IDRI), based in Seattle, manufactured the GLA-AF and CpG ODN 10104 adjuvants used in the trials. The CpG ODN 10104 adjuvant was originally developed by Pfizer. Aeras, based in Rockville, Md., manufactured the Na-GST-1 hookworm vaccine used in the studies, while Fraunhofer, based in Newark, Del., and the Walter Reed Army Institute of Research, based in Rockville, Md., manufactured the Na-APR-1 (M74) hookworm vaccine antigen…